Skip to content

A comparative study where patients suffering from Nidranash (Insomnia) will be given either ayurvedic formulation (Swapa Vati) in tablet form or Tablet Melatonin an allopathic formulation for treating Nidranash (Insomnia).

Double-blind Randomized Controlled Trial to Evaluate the Effect of Swapa Vati in Nidranash (Insomnia).

Status
Recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/07/070998
Enrollment
200
Registered
2024-07-22
Start date
Unknown
Completion date
Unknown
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G470- Insomnia

Interventions

None listed

Sponsors

Dr Almas Yaser Khan
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1) Patients suffering from minimum 50 % of signs and symptoms of Nidranash and Insomnia Severity Index ranging from 8 to 21 from mild to moderate severity. 2) Patients suffering from both primary and secondary Insomnia irrespective of pre-existing systemic disease which is the causative factor for Insomnia.

Exclusion criteria

Exclusion criteria: 1)History or diagnosis of another sleep disorder like bipolar disorder, psychotic disorder post-traumatic stress disorder, current psychiatric disorder that requires advanced medication. 2)History of neurological disorder causing Insomnia. 3)History of substance abuse or dependence. 4)History or current evidence of a clinically significant cardiovascular disorder. 5)Patients taking medications falling under Schedule IV (Controlled Substances Act). (https://www.drugs.com/schedule-4-drugs.html) 6) Subject having night shift duty.

Design outcomes

Primary

MeasureTime frame
Pittsburgh Sleep Quality Index Sore and Insomnia Severity Index score will be taken as the as the assessment parametersTimepoint: Pittsburgh Sleep Quality Index score and Insomnia Severity Index score will be assessed in questionnaire form at screening visit, baseline visit, on 15th day and on 30th day.

Secondary

MeasureTime frame
The comparison of before & after improvement in Sleep latency in minutes & Sleep Efficiency in percentage will be considered as secondary outcomeTimepoint: Sleep latency in minutes & Sleep Efficiency in percentage will be assessed at Screening Visit, baseline visit, 15th day & 30th day

Countries

India

Contacts

Public ContactDr Almas Yaser Khan

Dr. D. Y. Patil Vidyapeeth (Deemed to be University), Pune

gunvantayurved@gmail.com9028321955

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026